Pharmaceuticals - Southern Europe

Southern Europe

The projected revenue in the Pharmaceuticals market for Southern Europe is expected to reach US$40.06bn in 2024.
Among the various markets, Oncology Drugs stands out as the largest, with a projected market volume of US$7.63bn in 2024.
The market is expected to exhibit a steady annual growth rate (CAGR 2024-2028) of 5.70%, leading to a market volume of US$50.00bn by 2028.
In a global context, United States is anticipated to generate the highest revenue, amounting to US$636.90bn in 2024.
In Southern Europe, Italy's pharmaceutical market is experiencing a surge in demand for generic drugs due to cost-saving measures.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

The Pharmaceuticals market in Southern Europe has been experiencing growth in recent years.

Customer preferences: Customers in Southern Europe have been increasingly demanding high-quality and innovative pharmaceutical products. They are willing to pay a premium for products that are effective and have minimal side effects. Additionally, there is a growing demand for personalized medicine and treatments that cater to specific patient needs.

Trends in the market: Spain, Italy, and Portugal are the largest pharmaceutical markets in Southern Europe. These countries have been experiencing steady growth in the pharmaceutical industry, driven by an aging population, increasing prevalence of chronic diseases, and rising healthcare expenditure. In Spain, the government has been implementing policies to encourage the use of generic drugs, which has led to a decline in the market share of branded pharmaceuticals. Italy has been focusing on reducing healthcare costs by promoting the use of biosimilars. Portugal has been investing in research and development to strengthen its pharmaceutical industry.

Local special circumstances: Southern Europe has a unique regulatory environment that affects the pharmaceutical industry. Each country has its own regulatory agency that approves and oversees the marketing of pharmaceutical products. Additionally, the healthcare systems in these countries are publicly funded, which means that the government plays a significant role in determining the prices of pharmaceutical products. The economic crisis in the region has also led to austerity measures that have impacted healthcare spending.

Underlying macroeconomic factors: The pharmaceutical industry in Southern Europe is influenced by macroeconomic factors such as GDP growth, inflation, and unemployment rates. The economic crisis in the region has led to a decline in GDP growth and an increase in unemployment rates, which has affected the purchasing power of consumers. Additionally, the pharmaceutical industry is sensitive to changes in healthcare policies and regulations, which can impact the profitability of pharmaceutical companies. Despite these challenges, the pharmaceutical industry in Southern Europe is expected to continue growing, driven by the increasing demand for innovative and personalized medicine.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.